A LARGE OPEN-LABEL, NON-COMPARATIVE, PHASE III STUDY OF THE MULTI-TARGETED KINASE INHIBITOR SORAFENIB IN EUROPEAN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA